Although ALT is a readily available, cheap, and minimally invasive screening test, twice the sex-specific cut-offs (≥44 IU/L for females and ≥50 IU/L for males) have low specificity to rule out NAFLD, which limits its use [50]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.